Baird analyst Joel Beatty raised the firm’s price target on Ambrx Biopharma to $11 from $4 and keeps an Outperform rating on the shares. The analyst said as far as data is concerned, we believe data in 2H23 from the ongoing dose escalation study of ARX788 for prostate cancer could move the stock higher, and also to a lesser extent updated data from the paused studies of ARX788 for breast cancer.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMAM:
